Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): What to Do When One Fails

How Tadalafil and Vardenafil Work: Same Target, Different Profiles

Both drugs block the enzyme phosphodiesterase type 5 (PDE5), which breaks down cyclic GMP in penile smooth muscle. More cyclic GMP means more relaxation of the corpus cavernosum and better blood flow during sexual stimulation. Neither drug causes an erection without stimulation. That shared mechanism explains why men often assume they are interchangeable, but the pharmacokinetic and selectivity differences matter clinically.

Receptor Selectivity

Tadalafil inhibits PDE5 and also inhibits PDE11, an enzyme expressed in skeletal muscle and the testes. The clinical significance of PDE11 inhibition is not fully established, though some men report mild myalgia. Vardenafil is more selective for PDE5 over PDE6 than sildenafil, which is why visual disturbances (a PDE6 effect) are less common with vardenafil than with sildenafil. Understanding these selectivity differences helps predict side-effect likelihood when switching.

Half-Life and Dosing Window

Tadalafil has a half-life of approximately 17.5 hours, giving it the well-known 36-hour activity window. This allows spontaneous intercourse without timing pressure. Vardenafil has a half-life of 4 to 5 hours. The orodispersible formulation (Staxyn, 10 mg) dissolves under the tongue and may reach peak plasma concentration slightly faster than the standard tablet, though bioavailability is not significantly different between the two forms. For men who need a defined, shorter window, vardenafil's profile can be preferable.

Food and Alcohol Interactions

Tadalafil absorption is not meaningfully affected by food or moderate alcohol. Vardenafil tablets show reduced peak concentration (Cmax) after a high-fat meal, an effect that can reduce perceived efficacy. The orodispersible vardenafil (Staxyn) should not be taken with any liquid and is absorbed through the oral mucosa, partially bypassing this food interaction. Men who consistently take vardenafil tablets after heavy meals may falsely conclude the drug is ineffective.

Efficacy Data: How Each Drug Performs in Clinical Trials

Tadalafil's Key Evidence

Brock et al. (J Urol 2002, N=179) demonstrated that tadalafil 20 mg produced successful intercourse attempts in 75% of attempts vs. 32% with placebo (P<0.001), with an IIEF erectile function domain score improvement of 7.0 points over baseline. That trial remains one of the foundational references for tadalafil on-demand dosing.

The daily dosing regimen (2.5 mg and 5 mg) was evaluated separately and shows that continuous low-dose tadalafil improves endothelial function over time, not just erection quality at the moment of dosing. This matters for men with vasculogenic ED.

Vardenafil's Key Evidence

Porst et al. (Int J Impot Res 2003, N=580) showed that vardenafil 20 mg produced a mean IIEF erectile function domain score improvement of 8.0 points vs. 1.9 points for placebo, and successful penetration rates of 80% vs. 52% at the 20 mg dose. That dataset confirmed vardenafil's efficacy across a broad range of ED etiologies including diabetes and post-radical prostatectomy.

Across major trials, the three first-line PDE5 inhibitors (sildenafil, tadalafil, vardenafil) show broadly similar efficacy when used correctly. Head-to-head superiority for one agent over another in unselected populations has not been consistently demonstrated.

What "Efficacy" Actually Means in Practice

Trial efficacy numbers are generated under controlled conditions where dosing instructions are carefully followed. Real-world failure rates are higher largely because of incorrect use: inadequate sexual stimulation, wrong timing relative to food or alcohol, doses that are too low, or too few attempts before declaring failure. The American Urological Association (AUA) guideline on erectile dysfunction states: "an adequate trial of a PDE5 inhibitor requires at least 4 sexual attempts at the maximum tolerated dose" before concluding non-response.

When Tadalafil Fails: Is Vardenafil Worth Trying?

Defining True Failure vs. Suboptimal Use

Before switching, a prescriber should confirm the patient completed a true adequate trial. Four specific checkpoints matter:

• Did the patient take the drug at the correct dose (tadalafil 20 mg on-demand, or tadalafil 5 mg daily for at least 4 weeks)?
• Was there adequate sexual stimulation?
• Was the drug taken on an empty or light-fat stomach (less relevant for tadalafil but critical for vardenafil)?
• Were complicating factors addressed (hypogonadism, uncontrolled diabetes, significant anxiety)?

If any of these four conditions were not met, the failure is suboptimal use, not pharmacological non-response. Correcting the use pattern before switching may resolve the problem without changing the drug.

Cross-Over Response Rates

Published cross-over data and meta-analyses consistently show that 50 to 70% of men who report failure with one PDE5 inhibitor respond to a second agent. A 2006 analysis by Hatzimouratidis and Hatzichristou in the European Urology journal found that among men who truly failed one PDE5 inhibitor under correct conditions, approximately 40 to 55% achieved clinically meaningful improvement after switching to a different agent. Men who failed due to suboptimal use had even higher switch-success rates approaching 70 to 80%.

Reasons to Prefer Vardenafil After Tadalafil Failure

Vardenafil may be a reasonable next choice after tadalafil fails in several scenarios:

• The man prefers a shorter activity window with less prolonged systemic exposure.
• Side effects with tadalafil (back pain from PDE11 inhibition, prolonged flushing) were limiting.
• Faster on-set is desired and the orodispersible Staxyn formulation is appealing.
• The patient does not require the dual indication for BPH symptom management that daily tadalafil 5 mg provides.

Vardenafil's higher PDE5/PDE6 selectivity compared to sildenafil may also benefit men who previously tried sildenafil and experienced visual disturbances, though this is less directly relevant when switching from tadalafil.

When Vardenafil Fails: Should You Move to Tadalafil?

Daily Tadalafil as a Physiological Reset

When vardenafil fails or produces inconsistent results, daily tadalafil 5 mg deserves specific consideration rather than simply trying tadalafil 20 mg on-demand. Daily dosing produces a steady-state plasma trough concentration that maintains continuous low-level PDE5 inhibition. This has been associated with improved endothelial function, reduced oxidative stress in corpus cavernosum tissue, and better baseline erectile function over 12-week periods compared to on-demand dosing alone.

For men with mild-to-moderate vasculogenic ED who found vardenafil "worked sometimes but not reliably," daily tadalafil 5 mg may restore the spontaneity and consistency they were missing.

The BPH Overlap Advantage

Tadalafil 5 mg daily is the only PDE5 inhibitor with FDA approval for both ED and lower urinary tract symptoms due to benign prostatic hyperplasia. Men older than 50 who report both erectile dysfunction and difficulty urinating or urinary urgency are particularly well-served by switching to daily tadalafil 5 mg. Vardenafil has no approved BPH indication.

Tadalafil After Vardenafil Cardiac Screening Note

The cardiovascular risk profile of switching from vardenafil to tadalafil is not significantly different since both agents are vasodilators with absolute contraindication with nitrates. Any man starting or switching a PDE5 inhibitor who has known cardiovascular disease should have a Princeton Consensus III-level risk stratification before proceeding. Low-risk patients (asymptomatic, well-controlled hypertension, stable angina not requiring nitrates) may proceed directly to a trial.

Side Effect Comparison: What Changes When You Switch

The following framework helps clinicians and patients anticipate which side effects may improve or worsen when switching between tadalafil and vardenafil.

| Side Effect | Tadalafil (generic) | Vardenafil (Levitra/Staxyn) | Switch Implication | |---|---|---|---| | Headache | 15% (dose-dependent) | 15 to 21% | Similar incidence; switching unlikely to resolve | | Flushing | 11% | 10 to 12% | Similar; both mediated by systemic vasodilation | | Back pain / myalgia | 6 to 9% (PDE11-related) | <2% | Switch to vardenafil may reduce back pain | | Visual disturbance | <2% | <1% | Vardenafil has lower PDE6 inhibition | | Dyspepsia | 10% | 4% | Switch to vardenafil may reduce dyspepsia | | Nasal congestion | 4% | 9 to 10% | Switch to vardenafil may worsen nasal congestion | | QTc prolongation | Not clinically significant | Mild QT effect reported | Relevant in men on Class IA/III antiarrhythmics |

The QTc point deserves elaboration. Vardenafil has a small but documented QT-prolonging effect. Men on type IA antiarrhythmics (quinidine, procainamide) or type III antiarrhythmics (amiodarone, sotalol) should not use vardenafil. Tadalafil does not carry this warning. For those men, tadalafil is the preferred agent if a PDE5 inhibitor is otherwise appropriate.

Drug Interactions That Affect the Switch Decision

CYP3A4 Inhibitors

Both tadalafil and vardenafil are metabolized primarily by CYP3A4. Strong inhibitors (ketoconazole, ritonavir, clarithromycin) increase plasma concentrations of both drugs. The prescribing information for vardenafil 10 mg requires dose reduction to 2.5 mg in the presence of strong CYP3A4 inhibitors. Tadalafil's prescribing information recommends a maximum single dose of 10 mg no more frequently than once every 72 hours with strong inhibitors. The practical implication: switching drugs does not eliminate the interaction problem, but dose adjustment thresholds differ.

Alpha-Blockers

Men on alpha-blockers for BPH or hypertension face additive hypotension risk with any PDE5 inhibitor. The vardenafil label requires at least a 6-hour separation from an alpha-blocker dose. Tadalafil 5 mg daily has been studied in combination with tamsulosin 0.4 mg without clinically significant hypotension in most men, making it a better fit for men already established on alpha-blocker therapy. Switching from vardenafil to daily tadalafil 5 mg in a man on tamsulosin is pharmacologically well-supported.

The Correct Switching Protocol

Clinicians and patients often switch PDE5 inhibitors without a structured plan, which leads to repeated suboptimal trials. A reasonable evidence-informed protocol:

1. Confirm the prior drug was trialed at maximum tolerated dose for at least 4 sexual attempts.
2. Identify and correct modifiable causes: low testosterone (check total testosterone, target 400 ng/dL minimum), poorly controlled blood glucose (HbA1c above 8% significantly impairs PDE5 inhibitor response), obesity, and psychogenic inhibition.
3. Select the new agent based on the side-effect profile, dosing-window preference, comorbidities (BPH, arrhythmia, alpha-blocker use), and formulation preference (tablet vs. Orodispersible).
4. Start vardenafil at 10 mg on-demand, or tadalafil at 10 mg on-demand (titrate to 20 mg if tolerated) or 5 mg daily.
5. Re-assess after 4 sexual attempts at the new drug's target dose before concluding failure.
6. If both tadalafil and vardenafil fail under optimal conditions, refer to urology for evaluation of vacuum erection devices, penile injection therapy (alprostadil), or surgical consultation.

Special Populations: Who Benefits Most From Each Agent

Men With Diabetes

Diabetic ED is often harder to treat because both neurogenic and vasculogenic mechanisms are impaired. In the Porst et al. (2003) trial, vardenafil retained efficacy in diabetic subgroups with IIEF domain score improvements of approximately 6.0 points at 20 mg vs. 1.2 points placebo in men with type 2 diabetes. Tadalafil daily dosing has similarly shown benefit in diabetic men over 12-week trials. Neither agent is clearly superior in this population, but daily tadalafil's continuous endothelial support mechanism may offer a marginal long-term advantage.

Men After Radical Prostatectomy

Post-prostatectomy ED is among the most treatment-resistant presentations. Nerve-sparing surgery preserves some cavernous nerve function, but recovery is slow. Both tadalafil and vardenafil show modest benefit in nerve-sparing post-prostatectomy patients, with better results in bilateral nerve-sparing vs. Unilateral. Daily tadalafil 5 mg has a specific body of evidence supporting penile rehabilitation after prostatectomy, though the AUA notes the overall evidence quality for rehabilitation remains moderate.

Men Over 65

Older men often have polypharmacy concerns and may be on alpha-blockers, antiarrhythmics, or nitrates. Age alone does not affect PDE5 inhibitor efficacy substantially, though starting doses should be conservative. The FDA label for both agents suggests starting at the lower dose (5 mg tadalafil, 5 mg vardenafil) in men over 65 years.

When Neither Drug Works: Next Steps

If both tadalafil and vardenafil have failed adequate trials, three pathways exist:

Intracavernosal injection (ICI) therapy. Alprostadil (prostaglandin E1) injected directly into the corpus cavernosum produces erections in approximately 70 to 80% of men for whom oral PDE5 inhibitors have failed, including men with complete neurological injury. The starting dose is typically 2.5 mcg, titrated up to 40 mcg under clinical supervision.

Vacuum erection device (VED). Non-pharmacological, no drug interactions, suitable for men on nitrates who cannot use any PDE5 inhibitor. Satisfaction rates are lower than ICI but the device is safe in virtually any cardiovascular risk category.

Penile prosthesis. Inflatable penile prosthesis implantation produces satisfaction rates above 90% in properly selected patients and is considered definitive treatment for refractory ED. It remains an option when all medical therapies fail.